CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • BLUE Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 8-K Filing

Bluebird bio (BLUE) 8-KOther Events

Filed: 8 Oct 21, 5:03pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Other Events; Financial Statements and Exhibits
    • Download Excel data file
    • View Excel data file
    BLUE similar filings
    • 4 Nov 21 Entry into a Material Definitive Agreement
    • 21 Oct 21 Other Events
    • 18 Oct 21 Departure of Directors or Certain Officers
    • 8 Oct 21 Other Events
    • 5 Oct 21 Departure of Directors or Certain Officers
    • 21 Sep 21 Other Events
    • 8 Sep 21 Business separation of bluebird and 2seventy expected to be completed in October 2021
    Filing view
    Share this filing

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    __________________________
    FORM 8-K
    __________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): October 8, 2021
    __________________________
    bluebird bio, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    _____________________________________________________________
    Delaware001-3596613-3680878
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
    60 Binney Street,
    Cambridge, MA
    02142
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: (339) 499-9300
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    _____________________________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.01 par value per shareBLUEThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 8.01    Other Events.

        On October 8, 2021, bluebird bio, Inc. (“bluebird”) issued a press release announcing an update on the upcoming planned business separation of its oncology program and portfolio into 2seventy bio, Inc. as a publicly traded company and the filing of 2seventy bio's Form 10 Registration Statement with the U.S. Securities and Exchange Commission.

    The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 9.01    Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.
    Description
    99.1
    Press release issued by bluebird bio, Inc. on October 8, 2021.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: October 8, 2021bluebird bio, Inc.
    By:/s/ Jason F. Cole
    Jason F. Cole
    Chief Operating and Legal Officer


    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn